Inclusion Criteria:

- Must be outpatient, not hospitalized

- Male Patient between ages 50-80, inclusive

- Histologically/Cytologically graded adenocarcinoma of the prostate

- Must have T1, T2 or T3a adenocarcinoma of the prostate

- Must be a candidate for radiation therapy. Hormone refractory patients excluded

- WHO/ECOG score of 0,1 or 2

Exclusion Criteria:

- NO evidence of urinary tract that would put the patient at risk inthe opinion of the
Investigator.

- Used the following treatments for prostate Cancer

*immunotherapy *chemotherapy *External Beam Radiation *brachytherapy *hormonal
therapy *biological response modifiers

- Prior Prostate Surgery (excluding TUNA or TURP)

- Undergone Orchiectomy, adrenalectomy, hypophysectomy or be receiving any product
which could alter the function of these organs

- Use of Investigational Drug, Biologic or device within five half-lives of its
physiological action or three months prior to base line, whichever is longer

- Over the counter or alternative medical therapies which have estrogenic or
anti-androgenic effect

- uncontrolled CHF within 6 months to baseline

- Myocardial Infarct, coronary vascular procedure or Clinically
SignificantCardiovascualr Disease within 6 months of baseline Visit

- Venious thrombosis with in 6 Months of Screening

- Uncontrolled Hypertension defined as >170/100 or Symptomatic Hypotension within 3
months of Baseline

- Inuslin dependant Diabetic Patients Must not administer in an anatomic region where
they will recieve Eligard.

- Drug or Alcohol Abuse 6 months prior to Baseline

- Other Serious Illness at the discretion of the Investigator

- Patients receiving anti-coagulant or anti-platlet medication must be on a stable dose
for 3 months prior to Baseline

- Hypersensitivity to GnRH, GnRH agonists